Articles

How the Cost of Cancer Treatments May Affect Treatment Decisions for Patients


Best Practices for Treating Adverse Events Associated With Pancreatic Cancer Therapies

In this fifth installment, Shubham Pant, MD, and Tanios Bekaii-Saab, MD, discuss the best practices for treating adverse events associated with treatments such as FOLFIRINOX or NALIRIFOX.

Read More

After adjusting for sociodemographic characteristics, the percentage of patients with dual or Medicaid-only coverage increased from 16.84% to 18.09% in expansion states and dropped from 14.14% to 12.62% in nonexpansion states
Read More

Key Side Effects That May Occur With First-Line Treatments for Patients With Pancreatic Cancer
In this fourth installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss the key side effects seen in clinical trials of first-line treatments for patients with pancreatic cancer.
Read More

The Importance of Median Progression-Free Survival in Oncology Clinical Trials
In this third installment, Michael Pishvaian, MD, PhD, and Tanios Bekaii-Saab, MD, discuss why median progression-free survival is so important when considering the various transformational trials in pancreatic cancer.
Read More

Median Overall Survival of First-Line Treatments for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
In this second installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss various first-line treatments for metastatic pancreatic ductal adenocarcinoma from the MPACT, PRODIGE-4, and NAPOLI 3 trials.
Read More

Evaluation of Patients for Pancreatic Cancer

In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer.

Read More

Artificial intelligence holds promise for detecting lung cancer if research presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer is any indicator.
Read More

Patients diagnosed with stage IV lung cancer displayed higher proportions of EGFR mutations compared to those without.
Read More

Page 5 of 330